Drug Patents owned by Teva Pharms Intl

1. List of Amrix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7829121 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(9 months from now)

US9375410 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(9 months from now)

US9399025 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(9 months from now)

US8877245 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(9 months from now)

US7544372 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(9 months from now)

US7820203 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(9 months from now)

US7790199 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(9 months from now)

US7387793 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Feb, 2025

(2 years from now)

Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 01 February, 2007

Treatment: Relief of muscle spasm

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of AMRIX before it's patent expiration?
More Information on Dosage

2. List of Synribo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6987103 TEVA PHARMS INTL Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
Oct, 2026

(3 years from now)

Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient

Market Authorisation Date: 26 October, 2012

Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml)

Dosage: POWDER;SUBCUTANEOUS

How can I launch a generic of SYNRIBO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in